ReviewFrontiers in bioengineering and biotechnology2026
Strategic selection of microbial cell factories for sustainable and application-specific terpenoid production.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terpenoids (isoprenoids) constitute one of the largest and most structurally diverse families of natural products with application ranging from flavors, pharmaceuticals to biofuels. Conventional extraction from plants is often limited by low yields, seasonal variability, and environmental constraints; whereas, chemical synthesis requires toxic chemicals and energy-intensive processes. Consequently, microbial cell factories have emerged as sustainable and industrially scalable alternatives for terpenoid biosynthesis. Different microorganisms possess distinct physiological and metabolic advantages, including efficient precursor supply, tolerance to toxic products, internal storage for hydrophobic compounds, utilization of renewable carbon sources, and compatibility with complex biosynthetic pathways. Furthermore, several microbial hosts have strains with Generally Recognized as Safe (GRAS) status, making them attractive candidates for food and nutraceutical applications, although their regulatory acceptance ultimately depends on the production strain, genetic modifications, manufacturing process, product, and intended use. In addition, photosynthetic cyanobacteria offer a promising platform for direct conversion of CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.